Protocols

AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier’s help

AstraZeneca has won a priority review for its anti-CD22 therapy moxetumomab for hairy cell leukemia. The pharma giant can now expect a decision on third-line use in the third quarter, marking another prospective advance for its critically important oncology pipeline.

→ With major help from Frazier Healthcare Partners, a stealthy gene therapy company from the University of Pennsylvania has secured $9.29 million in investment. Gene therapy pioneer James Wilson co-registered the company in 2016, the Philadelphia Inquirer notes, but has since been replaced on the board by Penn medical school vice dean Kevin Mahoney. Krishna Polu, a former CytomX chief medical officer who joined Frazier as an entrepreneur in residence, is the CEO. Several Frazier execs, including Patrick Heron and Tadataka Tamada, are also on the board.

→ Switzerland’s Glycemicon announced today that after a second closing, it has raised a total of $5.28 million (CHF 5.05 million) to advance cat and human studies of its neutraceuticals. The biotech is developing a pipeline of novel food products that manages prediabetes, the “gray area” between normal blood sugar levels and diabetes, as well as weight.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->